Insilico Medicine, Inc., a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces that Juvenescence.AI, its joint venture with Juvenescence Limited, has licensed its first compound family for clinical development.
- AVITA Medical expands management team to support launch of RECELL device to treat burns September 16, 2018
- Study shows BPA substitutes may cause same health issues as the original September 16, 2018
- Maple leaf extract could prevent wrinkles September 12, 2018
- 3384 September 12, 2018
- | Health September 12, 2018
- Good skin care practices can help teens to battle stubborn acne September 7, 2018